A Proposal for a Classification for Recurrent Endometrial Cancer: Analysis of a French Multicenter Database From the FRANCOGYN Study Group. Issue 7 (September 2018)

• Record Type: Journal Article
• Authors: Bricou, Alexandre; Bendifallah, Sofiane; Daix-Moreux, Mathilde; Ouldamer, Lobna; Lavoue, Vincent; Benbara, Amélie; Huchon, Cyrille; Canlorbe, Geoffroy; Raimond, Emilie; Coutant, Charles; Graesslin, Olivier; Collinet, Pierre; Carcopino, Xavier; Touboul, Cyril; Daraï, Emile; Carbillon, Lionel; Ballester, Marcos
• Is Part Of: International journal of gynecological cancer. Volume 28:Issue 7(2018)
• Publication Date: 2018-09
• Subjects: Endometrial cancer -- Recurrences -- Relapses -- Classification; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000001296
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: Endometrial cancer (EC) recurrences are relatively common with no standardized way of describing them. We propose a new classification for them called locoregional, nodal, metastasis, carcinomatosis recurrences (rLMNC). Patients and Methods: The data of 1230 women with EC who were initially treated by primary surgery were included in this French multicenter retrospective study. Recurrences were classified based on dissemination pathways: (1) locoregional recurrence (rL); (2) nodal recurrence (rN) for lymphatic pathway; (3) distant organ recurrence (rM) for hematogenous pathway; and (4) carcinomatosis recurrence (rC) for peritoneal pathway. These pathways were further divided into subgroups. We compared recurrence free survival and overall survival (OS) between the 4 groups (rL/rN/rM/rC). Results: The median follow-up was 35.6 months (range, 1.70–167.60). One hundred ninety-eight women (18.2%) experienced a recurrence: 150 (75.8%) experienced a single-pathway recurrence and 48 (24.2%) a multiple-pathway recurrence. The 5-year OS was 34.1% (95% confidence interval [CI], 27.02%–43.1%), and the median time to first recurrence was 18.9 months (range, 0–152 months). The median survival after recurrence was 14.8 months (95% CI, 11.7–18.8). Among women with single pathway of recurrence, a difference in 5-year OS ( P < 0.001) and survival after recurrence ( P < 0.01) was found between the 4 rLNMC groups. The carcinomatosis group had the worst prognosis compared with other single recurrence pathways. Women with multiple recurrences had poorer 5-year OS ( P < 0.001) and survival after recurrence ( P < 0.01) than those with single metastasis recurrence, other than women with peritoneal carcinomatosis. Conclusions: This easy-to-use and intuitive classification may be helpful to define EC recurrence risk groups and develop guidelines for the management of recurrence. Its prognosis value could also be a tool to select homogenous populations for further trials. Abstract : Supplemental digital content is available in the text.